Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (Nasdaq: SDGR) announced that its clinical stage MALT1 inhibitor, SGR-1505, has received Fast Track designation from the FDA for treating adult patients with Waldenström macroglobulinemia who have failed at least two lines of therapy, including a BTK inhibitor.

The drug is currently in Phase 1 clinical trials for relapsed/refractory B-cell malignancies, showing encouraging preliminary efficacy and a favorable safety profile. Initial data was presented at recent medical conferences, demonstrating positive results in multiple B-cell malignancy subtypes. The FDA previously granted orphan drug designation to SGR-1505 for Mantle Cell Lymphoma in August 2023.

Schrödinger (NASDAQ: SDGR) announced the granting of restricted stock units (RSUs) to five newly hired employees on June 13, 2025. The grants, totaling 10,290 shares of common stock, were made under the company's 2021 Inducement Equity Incentive Plan and approved by the board's compensation committee. The RSUs follow a four-year vesting schedule, with 25% vesting after 12 months of continuous service and the remaining 75% vesting in equal yearly installments over the following three years. These grants were provided as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (NASDAQ: SDGR) announced promising initial Phase 1 clinical data for SGR-1505 in treating relapsed/refractory B-cell malignancies. The study involved 49 patients with various conditions including CLL/SLL, DLBCL, and Waldenström macroglobulinemia. SGR-1505 demonstrated a favorable safety profile with no dose-limiting toxicities, and showed clinical activity with a 22% overall response rate across all dose levels. Notable responses were observed in patients with indolent disease, including those previously treated with BTK and BCL-2 inhibitors. The drug achieved its pharmacodynamic target of ~90% IL-2 inhibition at doses ≥150 mg QD. Only 43% of patients experienced treatment-related adverse events, with rash and fatigue being most common at 12% each. The company plans to discuss the recommended Phase 2 dose with the FDA later this year.

Schrödinger (SDGR) has granted inducement equity awards to its newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian, who joined on May 28, 2025. The compensation package includes a non-statutory stock option to purchase 84,375 shares at $21.44 per share and 14,063 restricted stock units (RSUs). The stock options have a ten-year term with 25% vesting after one year and the remainder vesting monthly over three years. The RSUs vest over four years, with 25% vesting after the first year and the remaining vesting annually over three years.

["-"]

Schrödinger (NASDAQ: SDGR) has appointed Mannix Aklian as Executive Vice President, Chief Commercial Officer, and Global Head of Software Sales and Marketing. With over 25 years of experience in software sales and leadership within biopharmaceutical and technology industries, Aklian will oversee global account management teams and drive the company's software business growth. He joins from Certara, where he served as Senior Vice President of Global Software Sales, and previously held the position of CEO at LI, Inc. Aklian holds both B.S. and M.S. degrees in Molecular Biology from Tufts University.

Schrödinger (NASDAQ: SDGR) has granted restricted stock units (RSUs) for 7,051 shares to seven newly hired employees on May 21, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee. The RSUs follow a four-year vesting schedule: 25% vests after 12 months of continuous service, followed by equal yearly installments of 1/4 over the next three years. These grants serve as material inducement for employment compensation and comply with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (SDGR) announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, June 4, 2025, at 1:25 p.m. ET. Investors and interested parties can access the live webcast through the "Investors" section of Schrödinger's website. The presentation recording will remain available on the company's website for approximately 90 days after the event.

Schrödinger (NASDAQ: SDGR) announced a leadership transition as Geoffrey Porges will step down as CFO, with Richie Jain appointed as his successor. Jain, previously serving as SVP of Strategic Finance and Head of Corporate Development, brings extensive experience from Morgan Stanley where he was a managing director in healthcare investment banking. Dr. Porges will remain as an advisor until June 6, 2025, ensuring a smooth transition. In his new role, Jain will oversee financial operations, strategic planning, investor relations, and business development. The company has reaffirmed its financial guidance for Q2 2025 software revenue and full-year 2025 expectations, maintaining stability during this transition.

Schrödinger (SDGR) announced upcoming presentations of initial Phase 1 clinical data for SGR-1505, their investigational MALT1 inhibitor, at two major conferences. The data will be presented at the European Hematology Association Annual Congress (June 12-15, 2025, Milan) and the International Conference on Malignant Lymphoma (June 17-21, 2025, Lugano).

The Phase 1 study evaluates SGR-1505's safety, tolerability, and anti-tumor activity in patients with relapsed/refractory B-cell malignancies. The presentations will include initial safety, pharmacokinetic and pharmacodynamic data, plus preliminary efficacy data across various dosing levels. The company will host a webcast to discuss the data on June 12, 2025, at 8:00 a.m. ET.